Both Hodgkin's lymphoma and non-Hodgkin's lymphoma are lymphomas - a type of cancer that begins in a subset of white blood cells called lymphocytes. Lymphocytes are an integral part of your immune system, which protects you from germs.

Norman E. Sharpless, M.D., took the oath of office late Tuesday, October 17, 2017, to become the 15th director of the National Cancer Institute (NCI), part of the National Institutes of Health. He succeeds Harold E. Varmus, M.D., who stepped down as director in March 2015. Douglas R. Lowy, M.D., has been NCI's acting director since April 2015.

Tests that estimate ovarian reserve, or the number of a woman's remaining eggs, before menopause, do not appear to predict short-term chances of conception, according to a National Institutes of Health-funded study of women with no history of infertility. The study appears in the Journal of the American Medical Association.

If confirmed, Robert M. Weaver of Oklahoma will serve as Director of the Indian Health Service, Department of Health and Human Services, for a term of four years. 

The National Institute on Minority Health and Health Disparities (NIMHD), part of the National Institutes of Health, will fund seven new awards to support the Research Centers in Minority Institutions (RCMI) Specialized Centers program. RCMI is designed to support institutional research capacity and foster the career development of new and early career investigators conducting minority health and health disparities research. The centers will share approximately $122 million over five years, pending available funds.

The National Institutes of Health's High-Risk, High-Reward Research program, part of the NIH Common Fund, funded 86 awards to exceptionally creative scientists proposing to use highly innovative approaches to tackle major challenges in biomedical research. The program supports high-risk ideas with high-impact potential, such as recording the history of an individual cell in its DNA for future playback; understanding how bacteria in the microbiome can share anti-drug-resistance genes among themselves; resetting the immune system to allow universal organ transplants; and reimagining clinical trials to make them more personalized and more effective.